Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / EDRN Longitudinal Serum Biorepository

EDRN Longitudinal Serum Biorepository

122
Lynch, HenryCreighton University
Lynch, HenryCreighton University

No involved investigator sites defined.

UNKNOWN
Breast and Gynecologic Cancers Research

Four percent of EDRN Registry mutation carriers developed cancer within a year after beginning follow-up in this registry; within 2 years, 10% had developed cancer. Within 2 years, 17% had developed either a cancer or a pre-malignant lesion (e.g. adenoma). Our goal is to recruit 265 mutation carriers from the EDRN High Risk Registry and Hereditary Cancer Center for the Longitudinal Serum Biorepository (LSB). Based on the cancer rates observed to date in the EDRN Registry, four years of follow-up in a group of this size would be expected to yield 53 invasive and in situ cancers and 37 benign premalignant lesions. All subjects in the serum biorepository (1)have signed consent (2) are counseled carriers (APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6) and (3) are enrolled in family studies through CU's Department of Preventive Medicine and/or are enrolled in the EDRN High Risk Registry. Post specimen medical history is collected annually. Serum and plasma are aliquoted for respository storage and stored in labeled cryovials in an ultra low temperature (-86C) freezer. Specimens in the LSB are available for use in EDRN biomarker development and validation studies.

To develop a longitudinal serum biorepository with annual serial samples collected from mutation carriers within the Hereditary Cancer Institute and High Risk Registry for retrospective evaluation of promising biomarkers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 04/26/2017

A new funding opportunity associated with the Beau Biden Cancer Moonshot Initiative, Integration and Validation of Emerging Technologies to Accelerate Cancer Research, has been released and is due May 10, 2017. Click here for more information.

Announcement 03/14/2017

Thank you to everyone who made the March 2017 EDRN Steering Committee Meeting a success. The next EDRN Steering Committee Meeting will be on September 12-14, 2017, in Seattle, WA.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.